Loading...
XPAR
TNG
Market cap122mUSD
Jul 10, Last price  
0.76EUR
Name

Transgene SA

Chart & Performance

D1W1MN
XPAR:TNG chart
P/E
—
P/S
222.77
EPS
—
Div Yield, %
—
Shrs. gr., 5y
11.53%
Rev. gr., 5y
-30.31%
Revenues
490k
-92.29%
5,546,00028,019,00013,949,00011,765,00014,112,00014,446,0003,928,0003,849,0002,490,0001,465,0002,346,0002,099,0001,335,00013,296,0002,981,0009,993,0003,126,0007,900,0006,353,000490,000
Net income
-38m
L+10.46%
-22,031,000-5,521,000-18,000,000-27,347,000-34,219,000-43,626,000-43,203,000-42,858,000-48,556,000-46,374,000-25,207,000-32,274,0008,026,000-18,804,000-18,450,000-20,004,000-32,810,000-22,328,000-33,971,000-37,524,000
CFO
-37m
L+56.00%
-19,538,000-2,073,000-23,387,000-18,720,000-24,929,000-44,162,000-51,294,000-50,185,000-54,236,000-45,152,000-33,585,000-35,370,000-28,381,000-22,413,000-28,742,000-31,943,000-20,303,000-34,671,000-23,548,000-36,736,000

Notes

No notes on this company yet
Write a private note on this company, for your eyes only
Add note

Profile

Transgene SA, a French biotechnology firm headquartered in Illkirch-Graffenstaden, specializes in designing and developing groundbreaking therapeutic vaccines and oncolytic viruses to combat cancer and infectious diseases. Founded in 1979 and operating as a subsidiary of TSGH SAS, the company maintains a robust pipeline of treatments. This includes TG4050, a therapeutic vaccine in Phase I clinical trials for ovarian cancer and HPV-negative head and neck cancers, and TG4001, another therapeutic vaccine currently in Phase II for HPV-positive cancers. Its oncolytic virus programs feature TG6002, undergoing Phase I/IIa trials for various solid tumors, specifically gastrointestinal adenocarcinomas impacting the stomach, pancreas, and colon, as well as BT-001, an oncolytic virus in Phase I/II for solid tumors. Furthermore, Transgene is progressing TG1050, a therapeutic vaccine for chronic hepatitis B, and Pexa-Vec, an oncolytic virus targeting solid tumors. The company has established a comprehensive network of partnerships, encompassing strategic collaborations with major players like AstraZeneca, Merck KGaA, Pfizer, PersonGen BioTherapeutics, and NEC Corporation, alongside licensing agreements with SillaJen, Ascend BioPharmaceutical, and Valneva, and additional agreements with Sanofi, BioInvent, and Randox.
URL
https://www.transgene.fr
IPO date
Mar 25, 1998
Employees
146
Domiciled in
FR
Incorporated in
FR

Valuation

Title
EUR in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT